iHateHospitals.com

CANCER NEWS: Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week’s issue of Science. The article is available at www.sciencemag.org. Blinatumomab is being co-developed with MedImmune. Blinatumomab is [...]

MEDICAL NEWS: The ADEPT software package is not a statistical method in its own right as implied by Gerke and Siedentop (Statist. Med. 2008; DOI: ). ADEPT implements two-parameter CRM models as described in O’Quigley et al. (Biometrics 1990; 46(1):33-48). All of the basic ideas (use of a two-parameter logistic model, use of a [...]

MEDICAL NEWS: Partial verification refers to the situation where a subset of patients is not verified by the reference (gold) standard and is excluded from the analysis. If partial verification is present, the observed (naive) measures of accuracy such as sensitivity and specificity are most likely to be biased. Recently, Harel and Zhou showed [...]

MEDICAL NEWS: Partial verification refers to the situation where a subset of patients is not verified by the reference (gold) standard and is excluded from the analysis. If partial verification is present, the observed (naive) measures of accuracy such as sensitivity and specificity are most likely to be biased. Recently, Harel and Zhou showed [...]

MEDICAL NEWS: Background:
Animal data show that decreased activity of placental 11-beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), which potently inactivates glucocorticoids (e.g. cortisol) to inert forms (cortisone), allows increased access of maternal glucocorticoids to the fetus and ‘programs’ hypertension. Data in humans are limited. We examined in humans the association between venous umbilical cord blood [...]

DRUGS & RX: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug 27, 2008 - Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced the publication of preclinical data…

View the source of this article…

Curis Announces Nature Publication Elucidating a Paracrine Mechanism of Action in Hedgehog-Expressing Tumors was another wonderful [...]

DRUGS & RX: INDIANAPOLIS, August 26, 2008 /PRNewswire/ — Semafore Pharmaceuticals Inc. presented data at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., announcing the discovery of novel multi-targeted kinase inhibitors…

View the source of this article…

Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors was another wonderful and informative drug and pharmaceutical article [...]

DRUGS & RX: PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–Aug 26, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The companies announced that new Phase II data…

View the source of this article…

Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program [...]

DRUGS & RX: INDIANAPOLIS, August 26, 2008 /PRNewswire/ — Semafore Pharmaceuticals Inc. announced data presented at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., showing additional antiangiogenic activity of…

View the source of this article…

SF1126, Semafore’s PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell [...]

DRUGS & RX: MENLO PARK, Calif., August 26, 2008 /PRNewswire-FirstCall/ — XTENT, Inc. today announced that the positive one-year follow-up data from the CUSTOM II trial was published in the most recent issue of the peer-reviewed journal, EuroIntervention. The…

View the source of this article…

XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention was another [...]

DRUGS & RX: STOCKHOLM, SWEDEN, August 26, 2008 - Pharmalink AB today announces positive results from a follow-on Phase III study of Xepol, its candidate for the treatment of post-polio syndrome (PPS). The data have shown the candidate to be effective and…

View the source of this article…

Pharmalink Reports Positive Phase III Results for Xepol, a [...]

DRUGS & RX: BALTIMORE, August 26, 2008 /PRNewswire-USNewswire/ — Data by Dr. Bart Classen in The Open Endocrinology Journal provides further evidence that epidemics of childhood obesity, type 2 diabetes and metabolic syndrome are the result of exposure to the…

View the source of this article…

More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes [...]